SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH H impact

DocMorris Tightens FY26 Revenue Guidance

DocMorris announced an update to its financial outlook for the 2026 fiscal year, raising its expected external revenue growth to around 15 percent, compared to the previous guidance range of 12.5 to 15 percent. This adjustment follows accelerated growth in the company's prescription medicines (Rx) business, which saw an increase of over 90 percent in October compared to the same period last year. Consequently, the company now anticipates Rx growth of approximately 60 percent for the full year. Other annual and medium-term financial targets remain unchanged. Management continues to pursue its strategy of becoming a leading digital health companion, supported by recent initiatives such as the acquisition of the Swiss telemedicine provider Medi24.

DOCM

Related stories